Jake...{ don't buy the reformatting picture at all...these
Jake...{ don't buy the reformatting picture at all...these missing five had their Bios already addressed at their arrival to Cytodyn...what could be added in less than a year...and why All five at the same time.?..doesn't wash imho.
WHY not leave it up on the site... and whatever they felt that needed to be changed...work on the content in the background,...and then replace it...no hits...no runs...NO Errors...(such as giving the naysayers opportunity to blab).
This does not meet the standard of management 101...this is purely lame.
Interesting to see IF,...they address this at all.
Once again,...I can't fathom the strategy...have to wait and see how it plays out.
8
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Next PR Launches Innovative AI Optimization Services Next PR, an award-winning public relations firm, has recently introduced its AI Optimization Services, aimed at helping brands maintain visibility and authority in today's AI-driven digital landscape. As companies strive to adapt to the ever-changing world of artificial intelligence and search engine results generated...
Continue Reading
Overview of the Security and Vulnerability Management Market The Security and Vulnerability Management Market is on an impressive trajectory, predicted to expand from USD 17.55 billion to USD 24.07 billion by 2030, reflecting significant growth propelled by rising global vulnerabilities. Market Growth Drivers Multiple factors are contributing to this market's growth....
Continue Reading
Introducing Bybit.eu: A New Era for European Crypto Users Bybit, a leader in the cryptocurrency exchange market and the world's second-largest by trading volume, is evolving by launching Bybit.eu. This fully MiCAR-compliant platform is crafted specifically for users across the European Economic Area (EEA). Bybit EU GmbH operates this platform as a licensed Crypto-Asset...
Continue Reading
Nuvectis Pharma Reports Significant NXP900 Findings Nuvectis Pharma, Inc. (NASDAQ: NVCT), known for its pioneering work in oncology, has shared key insights regarding NXP900 at a recent prestigious cancer research meeting. This innovative drug shows considerable promise in treating advanced cancers. Based on a Phase 1a dose-escalation study, NXP900 demonstrated strong...
Continue Reading
The Unexpected Christmas Quest of Elon Musk Christmas is a time when many cherish the joy of giving and receiving gifts. However, when you are someone like Elon Musk, a dynamic CEO known for pushing boundaries with Tesla and SpaceX, a forgotten gift can turn into an extraordinary adventure. Imagine waking on Christmas Eve only to realize that you forgot to buy your...
Continue Reading
